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AbstrACt
Introduction Recurrent pregnancy loss (RPL) is defined 
as the spontaneous demise of two or more pregnancies 
before the fetus reaches viability. Despite investigation 
of multiple known maternal risk factors, in more than 
50% of couples, this condition remains unexplained. 
Studies focusing on paternal factors in RPL are scarce, 
and therefore, paternal evaluation in RPL is currently very 
limited. However, regarding single miscarriage, there 
are multiple publications suggesting a contributive role 
of paternal factors. In this project, we aim to identify 
paternal factors associated with RPL and to improve 
couple- specific prediction of future pregnancy outcomes 
by developing a prediction model containing both maternal 
and paternal factors.
Methods and analysis In a case–control design, 
the relation between unexplained RPL and paternal 
age, lifestyle factors, sperm DNA damage and 
immunomodulatory factors in peripheral blood and semen 
will be studied. Prospectively, 135 couples with naturally 
conceived unexplained RPL (cases) and 135 fertile 
couples without a history of pregnancy loss (controls) 
will be included, with collection of paternal blood and 
semen samples and documentation of clinical and lifestyle 
characteristics. In addition, 600 couples from both groups 
will be included retrospectively. To adjust for confounders, 
multivariate logistic regression will be used. The predictive 
value of paternal and maternal factors will be studied 
in the total RPL cohort consisting of approximately 735 
couples. The primary outcome of the cohort study is live 
birth within 5 years after initial visit of the clinic. Secondary 
outcomes are ongoing pregnancy, time interval until next 
pregnancy and pregnancy complications.
Ethics and dissemination This project is approved by 
the Medical Research Ethics Committee of the Leiden 
University Medical Center. No risks or burden are 
expected from the study. The findings of this study will 
be disseminated via peer- reviewed publications and 
presentations at international conferences.
trial registration number NL7762
IntroduCtIon
Spontaneous pregnancy loss is the most 
common complication in human pregnancy, 
defined as the loss of conception before the 
fetus reaches viability (<24 weeks of gesta-
tion) and occurs in 10%–15% of clinically 
recognised pregnancies.1 2 Pregnancy loss is 
also often referred to as miscarriage; however, 
this term is recommended to be used for 
confirmed intrauterine pregnancy losses 
only.3 Recurrent pregnancy loss (RPL) is 
defined as two or more losses in one couple.1 
This condition affects approximately 1%–3% 
of all couples of reproductive age.4 5
RPL is a highly heterogeneous condi-
tion. Among the multifaceted risk factors 
are maternal acquired thrombophilia 
strengths and limitations of this study
 ► First large multicentre prospective study to investi-
gate the contribution of both paternal lifestyle and 
biological factors to the development of recurrent 
pregnancy loss (RPL).
 ► Extensive cohort of RPL couples that will provide 
sufficient data to develop a multivariable prediction 
model for future pregnancy outcomes.
 ► Generalisability of the outcomes is increased by 
the collaboration between two Dutch tertiary cen-
tres in different regions that serve a diverse patient 
population.
 ► Control of bias by adjustment for important maternal 
confounders, to investigate the independent effect 
of paternal factors on RPL.
 ► Observational studies on lifestyle factors are prone 
to response and recall bias; a potential limitation of 
this study.
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(antiphospholipid syndrome), structural uterine abnor-
malities, thyroid autoimmunity and parental balanced 
chromosomal translocations.6–12 Maternal age is a 
strong risk factor for pregnancy loss, mainly based on 
the increased prevalence of the fetal aneuploid abnor-
malities with advancing age.13 Maternal lifestyle factors, 
such as smoking, alcohol and caffeine consumption and 
adiposity, are also associated with RPL.14–19
Despite extensive investigations, a potential underlying 
condition cannot be identified in 50%–70% of couples 
that present with RPL.20 21 Limited understanding of 
underlying pathophysiological mechanisms means that 
options for effective interventions are lacking. Currently, 
no evidence- based therapeutic options are available for 
couples with unexplained RPL. Clinical management 
is either empirical or primarily focused on providing 
supportive care, which has been shown to have a benefi-
cial effect.22 Part of this supportive care is counselling on 
the prognosis and success rate of subsequent pregnancies 
in couples with RPL. Lund et al evaluated the prognosis 
of 987 women with RPL and found that 67% achieved 
a live birth within 5 years after first consultation.23 They 
showed that the chance of at least one subsequent live 
birth decreased significantly with increasing maternal 
age and cumulative number of preceding miscarriages. 
Other studies reported live birth rates ranging from 57% 
to 95%.24–26 This large variation might be explained by 
the use of different definitions for RPL (2 vs 3 losses, 
consecutive vs non- consecutive, primary vs secondary), 
by the degree of monitoring of the women and by inclu-
sion or exclusion of biochemical pregnancies in the defi-
nition of RPL.23 Nevertheless, these results demonstrate 
that although unidentified factors increasing the risk for 
pregnancy loss may exist, they do not necessarily prevent 
the development of a successful pregnancy. An essential 
part of the management of couples with RPL is to give 
trustworthy advice on the prognosis for a next pregnancy. 
However, the main limitation in current prognostic 
studies on unexplained RPL is the lack of adjustment for 
relevant risk factors, disabling the possibility of individual 
risk estimation.23 27
The investigation of paternal contribution to RPL 
is currently limited to exploring the male karyotype. 
When considering counselling at an individual level, 
paternal factors may be included to establish a couple 
specified prognosis. Since the oocyte and the spermato-
zoon contribute equally to the genome of the embryo, 
it is biologically plausible to think that part of the idio-
pathic RPL cases could be explained by paternal factors. 
Some studies have evaluated the effect of paternal risk 
factors such as age, smoking and somatic health factors 
on the development of miscarriages, though these studies 
are mostly restricted to single miscarriage or to couples 
undergoing assisted reproductive techniques (ART).28–30 
Following the absence of a consistent association between 
conventional semen parameters and RPL,31–38 the majority 
of recent studies addressing paternal factors and preg-
nancy losses focused on genetic defects, with sperm DNA 
fragmentation showing the most promising results. Both 
Robinson et al39 and Zhao et al40 showed in a meta- analysis 
that a high level of sperm DNA damage is associated with 
an increased miscarriage rate after in vitro fertilisation/
intracytoplasmic sperm injection (IVF/ICSI) treatment. 
Two other recent meta- analyses found an increased 
mean difference in sperm DNA fragmentation of 12% in 
male partners of women with RPL compared with men 
whose partners had successful pregnancies.41 42 However, 
prospective studies in RPL couples evaluating the predic-
tive value of sperm DNA fragmentation on future preg-
nancy outcomes are lacking.
In addition, imbalances in seminal immunomodulatory 
factors may contribute to the development of RPL. During 
pregnancy, the maternal immune system has to tolerate 
the presence of semiallogeneic cells in maternal tissue. 
Seminal fluid contains various signalling molecules that 
are thought to induce lymphocyte proliferation, affect 
natural killer cell activity and modify cytokine release 
from antigen presenting cells, resulting in tolerance 
towards paternal alloantigens.43–45 An optimal balance of 
proinflammatory and immunomodulatory factors seems 
to be necessary for the induction of immunological toler-
ance and the process of implantation and placentation.46 
Increased plasma levels of interleukin-18 (IL-18) and 
IL-8 and decreased levels of IL-11 were found to be nega-
tively correlated to fertilisation and implantation.47 48 In 
subfertile couples with normospermia, including a small 
subgroup with a history of RPL, decreased concentrations 
of IL-1β and increased interferon-γ (IFN-γ) were present 
in the seminal plasma.49 The same study also suggests a 
correlation between levels of proinflammatory and anti- 
inflammatory cytokines in paternal peripheral blood and 
reproductive outcome. In case of such correlations, cyto-
kine micropatterns in blood serum could serve as a proxy 
for those in the seminal plasma and could potentially be 
suitable as easily available prognostic markers in clinical 
practice. However, larger prospective studies are required 
to assess this.
In this study, we hypothesise that unexplained RPL is 
an issue stemming from both the female and the male. 
Our overall aims are to identify paternal factors that are 
associated with the development of this condition and 
to assess the predictive value of these factors for future 




To identify paternal factors that are associated with unex-
plained RPL.
Paternal factors that will be assessed are: age, smoking, 
alcohol intake, recreational drugs intake, caffeine intake, 
body mass index (BMI), level of sperm DNA fragmenta-
tion and immunomodulatory factors in seminal plasma 
and paternal peripheral blood.
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Figure 1 Schematic diagram of study design. For the case–control study the target for inclusion is 735 couples in each arm. 
Of these 735 couples, 600 will be included retrospectively (2012–2018) and 135 will be included prospectively (2019–2020). 
Semen and blood will be collected from prospectively included men only. Couples with RPL (cases) are also part of a cohort 
study. We aim to complete a 5- year follow- up of these couples, starting from their individual point of inclusion. Control couples 
will not be in follow- up. LUMC, Leiden University Medical Center; MC, Medical Center; REMI, REcurrent MIscarriages; RPL, 
recurrent pregnancy loss.
To assess the correlation between level of sperm DNA 
fragmentation and immunomodulatory factors in seminal 
plasma and paternal peripheral blood.
secondary objectives
To assess the prognostic effect of paternal factors on 
reproductive outcomes in couples with unexplained RPL.
To develop a prediction model containing both 
maternal and paternal factors to predict the chance of a 
successful pregnancy for couples with unexplained RPL.
MEthods And AnAlysIs
study design
The primary objectives are focused on aetiology and will 
be addressed in a case–control study. In this case–control 
study, paternal factors are compared between couples 
with RPL and control couples. The expected duration of 
the case–control study is 1 year.
The secondary objectives will be addressed in a retro-
spective and prospective cohort study of couples with 
RPL. For all couples, participating in the cohort study, we 
aim to complete a follow- up on pregnancy outcomes of 
5 years after first consultation.
A schematic overview of the study design is shown in 
figure 1.
Eligibility criteria
Inclusion criteria for RPL couples are:
 ► Unexplained RPL
According to the European Society of Human Repro-
duction and Embryology (ESHRE) RPL guideline1 
defined as the loss of ≥2 pregnancies in the current 
relationship, without any of the following known risk 
factors: parental chromosomal abnormalities, uterine 
abnormalities, acquired thrombophilia and thyroid 
autoimmunity. The definition includes all pregnancy 
losses before 24th week of gestation verified by ultra-
sonography or uterine curettage and histology and 
also non- visualised pregnancies (including biochem-
ical pregnancy loss and/or resolved and treated preg-
nancies of unknown location) verified by positive 
urine or serum hCG. If identified as such, ectopic and 
molar pregnancies are not included. Pregnancy losses 
do not need to be consecutive.
Exclusion criteria for RPL couples are:
 ► Known risk factors for RPL as defined above.
 ► Mental or legal incapability of either the male or 
female.
 ► Pregnancy after ART.
 ► Pregnancy after oocyte, embryo or spermatozoa 
donation.
 ► Loss of <2 pregnancies in the current relationship.
Inclusion criteria for control couples are:
 ► Proven fertility (ie, pregnant at the time of inclusion 
or previously experienced pregnancy in the same 
relationship).
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Date of birth, zip code, ethnicity, level of education, profession, body weight, height, general medical 
history, use of medication, family history, detailed obstetric history (parity, no of spontaneous pregnancy 
losses, ectopic pregnancies or induced abortions, modes of conception of previous births, modes 
of delivery of previous births, gestational age at previous births, complications during previous 
pregnancies and deliveries, birth weight, gender and Apgar score of children of previous births), lifestyle 
characteristics (smoking, alcohol, drugs and caffeine intake, physical exercise pattern).
Paternal 
characteristics
Date of birth, zip code, ethnicity, level of education, profession, body weight, height, general medical 
history, use of medication, family history, lifestyle characteristics (smoking, alcohol, drugs and caffeine 
intake, physical exercise pattern).
Results of (previous) 
investigations into 
known risk factors 
of RPL
Presence of antiphospholipid syndrome (anticardiolipin IgG and IgM, B2 glycoprotein I antibodies IgG 
and IgM, and lupus anticoagulans), parental chromosomal abnormalities, presence of thyroid antibodies, 
presence of uterine anomalies.
RPL, recurrent pregnancy loss.
Exclusion criteria for control couples are:
 ► Previous spontaneous pregnancy loss.
 ► One of the following conditions: parental chromo-
somal abnormalities, uterine abnormalities, acquired 
thrombophilia and thyroid autoimmunity (this will 
not be investigated, however, couples are excluded 
when it is known).
 ► Mental or legal incapability of either the male or 
female.
 ► Pregnancy after ART.
 ► Pregnancy after oocyte, embryo or spermatozoa 
donation.
study population and recruitment
Couples with RPL that visit the RPL outpatient clinic of 
Leiden University Medical Center (LUMC) or early preg-
nancy unit of Erasmus MC University Medical Center 
(Erasmus MC) will be assessed for eligibility. LUMC is the 
coordinating centre. Couples with RPL will be invited to 
participate at their intake visit (after they have been referred 
by their general practitioner or a referring hospital). After 
diagnostic investigations on known risk factors of RPL are 
completed, couples with unexplained RPL will be selected 
for inclusion. In addition, couples who visited the partici-
pating clinics in the period 2012–2019 will be included in 
retrospect. Couples with RPL will participate in both the 
case–control study and the cohort study.
Eligible couples visiting the antenatal outpatient clinic 
of LUMC during their pregnancy will be invited to partic-
ipate in the control group. Control couples will also be 
included in retrospect.
Study recruitment in the coordinating centre started 
in June 2019. Recruitment at Erasmus MC is expected to 
start in September 2019. All couples will receive written 
information about the study together with the informed 
consent form, which includes a request to obtain permis-
sion for gathering data from medical records and storage 
of biomaterial for additional analyses related to this 
study. Participants are informed that study participation 
is voluntary and that they are free to withdraw at any time 
without any consequences for subsequent care. In case 
of participation, the informed consent form should be 
signed prior to inclusion in the study.
study procedures
Collection of clinical characteristics
Data about obstetric and general medical history and 
lifestyle factors of all participating couples will be docu-
mented (table 1).
These data will be collected during consultations 
(in a semistandardised way using a template) and 
from medical records. Additional required data will be 
acquired via digital surveys that will be sent to partic-
ipating couples. Data entry and generation of digital 
surveys will be performed using Castor EDC.50
Couples with RPL participating in the cohort study will be 
in follow- up for a total time of 5 years after initial consulta-
tion. These couples will receive a digital survey once a year. 
This survey contains questions about outcomes of new preg-
nancies if applicable and changes in medical history and 
lifestyle in the past year. When couples with RPL are still 
in regular clinical follow- up, data will be collected during 
regular consultations and it will not be necessary to send a 
digital survey. Retrospectively included couples from whom 
(part of) the follow- up period is missing in their medical 
records, will receive a survey to ask for pregnancy outcomes 
in the missing time period.
Clinical characteristics of couples participating in the 
control group will be collected at one time point (during 
consultation at the antenatal clinic), directly followed by a 
digital survey containing questions about lifestyle related 
to the period prior to the index pregnancy. There is no 
follow- up of control couples.
Collection and analysis of samples
Male partners of participating couples will be asked for 
a peripheral blood sample and sperm sample acquired 
through masturbation. Samples will be collected from all 
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prospectively included men. This applies to both cases 
and controls. From all retrospectively included couples, 
only clinical data will be documented.
All samples will be processed and analysed in the labo-
ratory of Reproductive Immunology at LUMC. Samples 
will be collected once. Samples from other participating 
centres will be sent to LUMC for storage and analysis.
Semen samples will be stored in −20°C until time of 
analysis. Sperm DNA fragmentation will be detected 
by terminal deoxynucleotidyltransferase dUTP nick 
end labelling assay (APO- DIRECT Kit, BD Biosciences) 
following the manufacturer’s instructions. The level (%) 
of sperm DNA fragmentation will be determined by flow 
cytometric analysis.
The level of immunomodulatory factors in seminal 
plasma and peripheral blood will be assessed by Bio- 
Plex Luminex system assay (Bio- Rad Laboratories), 
following the manufacturer’s instructions. Samples will 
be analysed using a Bio- Plex Array Reader with Bio- Plex 
software. Through this assay quantification of cytokine 
levels including tumour necrosis factor-α, IFN-γ, trans-
forming growth factor-β1, IL-1β, IL-8, IL-10, IL-11, IL-18, 
sHLA- G and PGE2 will be performed. These cytokines 
were selected because previous small studies suggested 
correlations between concentrations in seminal plasma 
and/or paternal peripheral blood and reproductive 
outcome.47–49 51
Control of bias
Since the design of this study is observational, there is 
need to control and adjust for confounding factors. For 
example, maternal age is an important confounder for the 
effect of paternal age on RPL. To control for confounders, 
stratification and regression models will be used. Selec-
tion bias is minimised by a clear definition of the study 
population. In addition, the control couples are selected 
independently of their exposure and they represent the 
source population that generates the cases. Finally, infor-
mation bias is limited as much as possible by collecting 
information similarly from the cases and controls.
sample size calculation
Case–control study
Since sperm DNA fragmentation could be seen as a proxy 
for advanced age and also for the presence of smoking, 
obesity and excessive exercise, this factor was used for 
sample size calculations. Zhao et al40 evaluated the asso-
ciation between sperm DNA fragmentation and miscar-
riages after IVF/ICSI treatment in 2756 couples and 
they found a combined OR 2.28 (95% CI 1.55 to 3.35) 
for miscarriage in patients with high sperm DNA frag-
mentation The rate of high sperm DNA fragmentation 
was significantly higher in the group with miscarriage 
(34%) compared with the group with live births (19%). 
To detect this difference, using α=0.05 and power=80%, 
the sample size would be 135 in the RPL group and 
135 in the control group. Also the recent meta- analyses 
of Tan et al41 and McQueen et al42 have been taken into 
consideration for sample size calculation. They evaluated 
the mean difference in per cent sperm DNA fragmenta-
tion between RPL patients and fertile controls. However, 
based on these mean differences (both of approximately 
12%), the sample size would be very small (<10 per arm) 
and therefore not appropriate for this project, since we 
are not solely interested in sperm DNA fragmentation but 
also in other lifestyle and demographic factors.
Cohort study
No straightforward accepted methods exist to estimate 
the required number of subjects to develop a multivari-
able prediction model. Ideally, prognostic studies include 
several hundreds of patients who develop the outcome 
event.52 Various studies have suggested that for each candi-
date predictor studied, at least 10 events are required.53 54 
Currently, female age and number of previous pregnancy 
losses are the only known factors consistently shown to 
impact prognosis for future pregnancy outcomes.1 In 
addition to these factors, we intend to examine paternal 
factors for their predictive capacity. Assuming that at least 
two paternal factors will be included in the model, like 
age and BMI (and also maternal BMI), with four age cate-
gories (<30, 30–35, 35–40, >40 years), four categories for 
preceding pregnancy losses (2, 3, 4, ≥5) and four BMI 
categories (<18, 18–25, 25–30, >30 kg/m2), a minimum 
of 20×10 = 200 patients with RPL and live birth in subse-
quent pregnancy are necessary. We estimate that the total 
RPL cohort will eventually consist of approximately 735 
couples (with retrospective and prospective inclusions 
together, shown in figure 1) and we expect 70% of them 
to have a live birth within 5 years after initial consulta-
tion. Based on these numbers, it is feasible to develop a 
multivariable model to predict the chances for ongoing 
pregnancy and live birth within 5 years. We will include 
patients who visited the clinics between 2012 and 2019 
and also the couples (cases) of the case–control study.
study outcomes
In the case–control study, the following exposures will be 
studied:
 ► Smoking: documented as average number of ciga-
rettes per day. Also data on former smoking behaviour 
will be documented.
 ► Alcohol consumption: documented as average 
number of units per week.
 ► Recreational drug consumption: specified by type of 
drug, quantity and frequency.
 ► Caffeine intake: documented as average number of 
caffeinated drinks per day.
 ► Physical exercise pattern; documented as moderate 
to intensive physical exercise in days per week and 
minutes per day.
In the cohort study, the following outcomes will be 
studied:
 ► Live birth within 5 years after initial consultation 
(for this outcome we intend to develop a prediction 
model).
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 ► Ongoing pregnancy (>24 weeks).
 ► Time interval until next pregnancy.
 ► Pregnancy complications including fetal growth 
restriction, preterm birth, pregnancy induced hyper-
tension, pre- eclampsia, haemolysis elevated liver 




For the case–control study, proportions will be calcu-
lated for the dichotomous and categorial exposures with 
95% CIs. Comparison between the cases and controls is 
performed by a X2 test. Mean differences with 95% CIs 
are calculated to compare continuous variables between 
the groups. To correct for confounders (including 
maternal factors), stratified analyses and multivariate 
logistic regression including paternal and maternal vari-
ables that are highly correlated will be performed.
Cohort study
To indicate a relation between live birth and paternal 
(and maternal) factors as described above, first univariate 
logistic regression will be used. To select the most prog-
nostic set of variables logistic regression with shrinkage 
methods such as lasso will be used. Time to pregnancy is 
estimated using the Kaplan- Meier method. Only in the 
subgroup of prospectively included RPL couples (with 
collection of samples), blood and sperm investigations 
will be included in the analyses.
To cope with analysis of missing values, multiple 
imputation will be performed. Statistical analysis will be 
performed using SPSS Statistics V.25 (IBM SPSS Software) 
and/or R V.3.6.0. For all tests, a two- sided p<0.05 or 95% 
CI not including the null value is considered significant.
Patient and public involvement
During the development of the study protocol, the Dutch 
association for patients with fertility problems (Freya) was 
consulted. Results will be presented during their thematic 
meetings to inform patients about study progress. Social 
media will be used to highlight new publications and 
conference presentations.
EthICs And dIssEMInAtIon
This study will be conducted according to the princi-
ples of the Declaration of Helsinki.55 Ethics approval for 
this study was obtained at the Medical Research Ethics 
Committee of the Leiden University Medical Center. No 
risks or burden are expected from the study. No addi-
tional hospital visits are required.
Eligible couples obtain written information about the 
study objectives and procedures and they will have suffi-
cient time to decide on participating. All clinical data 
and data derived from surveys will be saved in the Castor 
EDC REMI III database. No data directly traceable to 
patients will be included in this database. Every couple 
will be assigned a unique code. This code will also be used 
to associate clinical data with corresponding blood and 
semen samples.
The findings of this study will be disseminated via peer- 
reviewed publications and presentations at international 
conferences.
dIsCussIon
RPL is often accompanied by psychological morbid-
ities such as depression and anxiety, making it a very 
distressing and costly condition.56 In current practice, 
RPL is mostly considered an issue derived exclusively 
from female causes. However, it is questionable whether 
this female- centred approach is correct, especially consid-
ering the substantial proportion of RPL cases that remains 
unexplained. In November 2017, the ESHRE developed 
a new guideline for the management of RPL, to supply 
healthcare providers with the best available evidence for 
investigation and treatment of RPL. Future research on 
the paternal contribution in RPL, such as the impact of 
paternal lifestyle factors and sperm DNA damage, was 
recommended by the guideline committee.1
In this project, we hypothesise that besides maternal 
factors, paternal factors are associated with the develop-
ment of RPL. Understanding the role of these factors 
contributing to the pathological mechanisms of RPL may 
provide new diagnostic tools and treatment options. To 
the best of our knowledge, this project includes the first 
large prospective cohort study evaluating the contribu-
tion of multiple paternal lifestyle and biological factors to 
unexplained RPL.
Limitations of all research on lifestyle factors using self- 
reported data are the phenomena of recall and response 
bias. Individuals might report biassed estimates of self- 
assessed behaviour for different reasons, including misun-
derstanding or social desirability. Although these types 
of bias will always be present to some extent, we try to 
minimise this by using standardised and well- structured 
surveys, by avoiding long recall periods as much as 
possible and by choosing an appropriate and well- defined 
control group.
Ultimately, we aim to develop a couple- specific model 
including both maternal and paternal factors to predict 
future reproductive outcomes in couples with unex-
plained RPL. Although not an intervention as such, 
counselling couples confronted with RPL about their 
individual prognosis is an essential part of the manage-
ment of these couples and allows them to decide for or 
against future pregnancy attempts. Moreover, this study 
might also provide new starting points for future treat-
ment options with regard to lifestyle interventions.
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